Novel ADC Boosts Survival in Pretreated Endometrial Cancer | HappeningNow.news
Published Date: November 10, 2026

Health · 2 views

Novel ADC Boosts Survival in Pretreated Endometrial Cancer

(MedPage Today) -- Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly…

Source Summary Published 2h 12m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 2 Community interest
Brief read Under 1 min brief 30 words

Summary

(MedPage Today) -- Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved

Read original at MedPage Today

Coverage Context

Part of ADC coverage 23 tracked stories
Explore ADC View timeline

More from Health

Continue reading recent Health coverage

Category Health
Source MedPage Today
Return to Frontpage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page